GSK Unveils $30 Billion U.S. Investment Amid Pharma Tariff Threat

GSK (GSK.L) announced plans to invest $30 billion in U.S. research, development, and supply chain infrastructure over the next five years. The move comes as U.S. President Donald Trump presses for greater domestic manufacturing and threatens to impose tariffs on the pharmaceutical sector.

Expanding U.S. Manufacturing and R&D

The investment includes $1.2 billion for a new factory in Upper Merion, Pennsylvania, dedicated to producing medicines for respiratory diseases and cancer, with construction scheduled to start in 2026. GSK will also enhance drug substance manufacturing and strengthen device and auto-injector assembly capabilities across its U.S. sites.

Strengthening Transatlantic Life Sciences

GSK said the expansion will integrate AI and advanced digital technologies across its five U.S. facilities, creating a stronger bridge between U.S. and UK operations. The company positioned the move as a step to reinforce both countries’ leadership in life sciences while navigating rising trade pressures.